PRINCETON, N.J., Oct. 26 /PRNewswire/ -- BullMarket.com (http://www.bullmarket.com/), an online investment newsletter focused on long-term growth and income-generating stocks, has provided...
CHICAGO, Sept. 4 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for EBAY, CAT, BNI, DAL, and XL. Seven Summits Strategic Investments' PriceWatch Alerts are available at...
DALLAS, March 23 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trade alerts for free by visiting...
DALLAS, Feb. 9 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trading notes for free by visiting:...
-- More than 21,000 patients on commercial and clinical therapy worldwide -- Elan Pharmaceuticals PLC Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced new data on...
RNS Number:1534W Vernalis PLC 08 May 2007 May 8, 2007 Biogen Idec and Vernalis Plc Announce the Start of Phase II Program of BIIB014 in Parkinson's Disease Cambridge, MA and...
Biogen IDEC New Data on TYSABRI(R) Presented at ECTRIMS Congress Demonstrate Significant Improvement in Cognitive Function in Patients with Multiple Sclerosis Biogen Idec (NASDAQ: BIIB) and Elan...
Biogen IDEC Data from GLANCE Safety Study Also Presented One-year data from the Phase III SENTINEL trial, presented at the 57th annual American Academy of Neurology (AAN) meeting in Miami Beach...
Elan Corporation PLC Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today a voluntary suspension in the marketing of TYSABRI(R) (natalizumab), a treatment for multiple...
Biogen IDEC Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today a voluntary suspension in the marketing of TYSABRI(R) (natalizumab), a treatment for multiple...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관